A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension

Background: Pulmonary arterial hypertension (PAH) is a progressive disorder characterised by raised pulmonary artery pressures with pathological changes in small pulmonary arteries. Previous studies have shown that approximately 70% of familial PAH and also 11–40% of idiopathic PAH (IPAH) cases have mutations in the bone morphogenetic protein receptor type II (BMPR2) gene. In addition, mutations in the activin receptor-like kinase 1 (ALK1) gene have been reported in PAH patients. Since both the BMPR2 and ALK1 belonging to the transforming growth factor (TGF)-β superfamily are known to predispose to PAH, mutations in other genes of the TGF-β/BMP signalling pathways may also predispose to PAH. Methods: We screened for mutations in ENDOGLIN(ENG), SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6 and SMAD8 genes, which are involved in the TGF-β/BMP signallings, in 23 patients with IPAH who had no mutations in BMPR2 or ALK1. Results: A nonsense mutation in SMAD8 designated c.606 C>A, p.C202X was identified in one patient. The father of this patient was also identified as having the same mutation. Functional analysis showed the truncated form of the SMAD8 C202X protein was not phosphorylated by constitutively active ALK3 and ALK1. The SMAD8 mutant was also unable to interact with SMAD4. The response to BMP was analysed using promoter-reporter activities with SMAD4 and/or ca-ALK3. The transcriptional activation of the SMAD8 mutant was inefficient compared with the SMAD8 wild type. Conclusion: We describe the first mutation in SMAD8 in a patient with IPAH. Our findings suggest the involvement of SMAD8 in the pathogenesis of PAH.

[1]  M. Furutani,et al.  Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[2]  S. Rosenkranz.  Pulmonary hypertension: current diagnosis and treatment , 2007, Clinical Research in Cardiology.

[3]  R. Matsuoka,et al.  Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy , 2007, Journal of Human Genetics.

[4]  J. Loyd,et al.  Genetics and mediators in pulmonary arterial hypertension. , 2007, Clinics in chest medicine.

[5]  J. Cogan,et al.  High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[6]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[7]  Gil Navon,et al.  Neotendon formation induced by manipulation of the Smad8 signalling pathway in mesenchymal stem cells. , 2006, The Journal of clinical investigation.

[8]  Ye Guang Chen,et al.  Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia. , 2006, Blood.

[9]  T. Oliver,et al.  Evidence that autocrine signaling through Bmpr1a regulates the proliferation, survival and morphogenetic behavior of distal lung epithelial cells. , 2006, Developmental biology.

[10]  J. Carlquist,et al.  Mutations of the TGF‐β type II receptor BMPR2 in pulmonary arterial hypertension , 2006, Human mutation.

[11]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[12]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[13]  N. Rudarakanchana,et al.  Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension , 2005, Circulation research.

[14]  R. Trembath,et al.  Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. , 2005, Circulation.

[15]  K. Miyazono,et al.  BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[16]  J. Kench,et al.  Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression , 2004, The Prostate.

[17]  S. Pinson,et al.  Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France , 2004, Human mutation.

[18]  S. Thiagalingam,et al.  Elucidation of Epigenetic Inactivation of SMAD8 in Cancer Using Targeted Expressed Gene Display , 2004, Cancer Research.

[19]  R. Trembath,et al.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia , 2003, Journal of medical genetics.

[20]  T. Nakajima,et al.  Endoglin Is Not a Major Susceptibility Gene for Intracranial Aneurysm Among Japanese , 2003, Stroke.

[21]  P. Thistlethwaite,et al.  Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.

[22]  K. Miyazono,et al.  Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. , 2002, Molecular biology of the cell.

[23]  N. Rudarakanchana,et al.  Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. , 2002, Human molecular genetics.

[24]  R. Trembath,et al.  Primary Pulmonary Hypertension Is Associated With Reduced Pulmonary Vascular Expression of Type II Bone Morphogenetic Protein Receptor , 2002, Circulation.

[25]  R. Speich,et al.  Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[26]  R. Trembath,et al.  Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-&bgr;1 and Bone Morphogenetic Proteins , 2001, Circulation.

[27]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[28]  M. Humbert,et al.  BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. , 2001, American journal of human genetics.

[29]  M. Humbert,et al.  Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family , 2000, Journal of medical genetics.

[30]  S. Hodge,et al.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.

[31]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[32]  R. Baron,et al.  Mouse smad8 phosphorylation downstream of BMP receptors ALK-2, ALK-3, and ALK-6 induces its association with Smad4 and transcriptional activity. , 2000, Biochemical and biophysical research communications.

[33]  K. Miyazono,et al.  Smad6 Is a Smad1/5-induced Smad Inhibitor , 2000, The Journal of Biological Chemistry.

[34]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[35]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[36]  S. Little,et al.  Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. , 1992, American journal of human genetics.

[37]  J. Massagué,et al.  TGF beta signals through a heteromeric protein kinase receptor complex. , 1992, Cell.

[38]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[39]  H. Satoh,et al.  Regional location of a novel yes-related proto-oncogene, syn, on human chromosome 6 at band q21. , 1986, Japanese journal of cancer research : Gann.